Cardiovascular disease and COVID-19: les liaisons dangereuses

Patients with cardiovascular risk factors or established cardiovascular disease have an increased risk of developing coronavirus disease 19 and have a worse outcome when infected, but translating this notion into effective action is challenging. At present it is unclear whether cardiovascular therapies may reduce the likelihood of infection, or improve the survival of infected patients. Given the crucial importance of this issue for clinical cardiologists and all specialists dealing with coronavirus disease 19, we tried to recapitulate the current evidence and provide some practical recommendations.

[1]  Xin Li,et al.  COVID-19 with Different Severities: A Multicenter Study of Clinical Features , 2020, American journal of respiratory and critical care medicine.

[2]  Xiaowei Yan,et al.  Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 , 2020, The New England journal of medicine.

[3]  E. Marbán,et al.  COVID-19 and the Heart , 2020, Circulation research.

[4]  M. Nishimura,et al.  Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations , 2020, The Lancet Respiratory Medicine.

[5]  M. Lazanas,et al.  The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design , 2020, Hellenic Journal of Cardiology.

[6]  M. Huang,et al.  Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 , 2020, Journal of Thrombosis and Thrombolysis.

[7]  Marc A Pfeffer,et al.  Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 , 2020, The New England journal of medicine.

[8]  G. Danzi,et al.  Acute pulmonary embolism and COVID-19 pneumonia: a random association? , 2020, European heart journal.

[9]  Tao Guo,et al.  Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[10]  Dengju Li,et al.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.

[11]  G. Iacobellis.  COVID-19 and diabetes: Can DPP4 inhibition play a role? , 2020, Diabetes Research and Clinical Practice.

[12]  Ke Ma,et al.  Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study , 2020, BMJ.

[13]  A. Akbari,et al.  Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis , 2020, Archives of academic emergency medicine.

[14]  D. Lillicrap.  Disseminated intravascular coagulation in patients with 2019‐nCoV pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[15]  Refugio en el Lugar,et al.  COVID-19 (Coronavirus). , 2020, Lymphatic research and biology.

[16]  Beijing China. Prevention,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China , 2020 .

[17]  Fenglian Ma,et al.  Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin , 2020, European heart journal.

[18]  F. Welt,et al.  Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic , 2020, Journal of the American College of Cardiology.

[19]  Hong Jiang,et al.  Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up , 2020, Journal of Infection.

[20]  Zhaofeng Chen,et al.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.

[21]  Bo Li,et al.  Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China , 2020, Clinical Research in Cardiology.

[22]  N. Zhong,et al.  Clinical Characteristics of Coronavirus Pneumonia 2019 (COVID-19): An Updated Systematic Review , 2020, medRxiv.

[23]  D. Brodie,et al.  The Variety of Cardiovascular Presentations of COVID-19 , 2020, Circulation.

[24]  D. Gurwitz.  Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics , 2020, Drug development research.

[25]  Qiurong Ruan,et al.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.

[26]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target , 2020, Intensive Care Medicine.

[27]  Mairie de Savas.  COVID-19, Coronavirus , 2020 .

[28]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[29]  Wei Wang,et al.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.

[30]  Ting Yu,et al.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.

[31]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[32]  Dengju Li,et al.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[33]  Lei Liu,et al.  Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury , 2020, Science China Life Sciences.

[34]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[35]  M. Frieman,et al.  Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. , 2019, JCI insight.

[36]  A. Arroliga,et al.  Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia , 2018, Proceedings.

[37]  W. Tan,et al.  Targeting the renin–angiotensin system as novel therapeutic strategy for pulmonary diseases , 2018, Current opinion in pharmacology.

[38]  T. Rice,et al.  A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension , 2018, European Respiratory Journal.

[39]  A. Badawi,et al.  Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis , 2016, International Journal of Infectious Diseases.

[40]  K. Baumstarck,et al.  Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. , 2013, JAMA.

[41]  D. Fedson.  Treating influenza with statins and other immunomodulatory agents. , 2013, Antiviral research.

[42]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[43]  M. Fine,et al.  Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  D. Caldeira,et al.  Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[45]  A. Komnos,et al.  Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: Open-label, randomized study* , 2011, Critical care medicine.

[46]  Liam Smeeth,et al.  Effect of statin treatment on short term mortality after pneumonia episode: cohort study , 2011, BMJ : British Medical Journal.

[47]  D M Fleming,et al.  An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998–1999 to 2005–2006 , 2010, Epidemiology and Infection.

[48]  D. Redelmeier,et al.  Influenza Morbidity and Mortality in Elderly Patients Receiving Statins: A Cohort Study , 2009, PloS one.

[49]  E. Schiffrin,et al.  Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. , 2007, Clinical science.

[50]  B. Skipper,et al.  Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. , 2007, Chest.

[51]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[52]  Y. Chan,et al.  Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS) , 2003, Thorax.

[53]  Elizabeth Rea,et al.  Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. , 2003, JAMA.

[54]  V. Fuster,et al.  Coronary plaque disruption. , 1995, Circulation.

[55]  K. Shimamoto,et al.  Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. , 2015, American journal of hypertension.

[56]  W. Schaffner,et al.  Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. , 2012, The Journal of infectious diseases.